There are 412 resources available
1452P - Factors associated with real-world (rw) outcomes among pts with metastatic NSCLC (mNSCLC) receiving select immuno-oncology (IO) regimens: CORRELATE
Presenter: Stephen Liu
Session: Poster session 20
2147P - Thrombotic recurrence and bleeding complications in non-small cell lung carcinoma (NSCLC) patients with venous thromboembolism (VTE)
Presenter: Irene Gonzalez Caraballo
Session: Poster session 07
1350P - Survival benefits of local treatment (LT) for brain metastases (BMs) in patients (pts) with EGFR-mutant non-small cell lung cancer (EGFR-mt NSCLC) treated with osimertinib
Presenter: Takehiro Tozuka
Session: Poster session 19
1016O - Autoimmunity against surfactant protein B drives immune checkpoint inhibitor-related pneumonitis in patients with NSCLC
Presenter: Lukas Flatz
Session: Proffered Paper session - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
669P - Patient-reported outcomes with selpercatinib in patients with RET-driven cancers in the phase I/II LIBRETTO-001 trial
Presenter: Hyunseok Kang
Session: Poster session 17
1273P - The prognostic value evaluation of a tissue Comprehensive Genomic Profiling (CGP)-informed personalized MRD detection assay in NSCLC
Presenter: Wei Gao
Session: Poster session 04
1434P - Machine learning features derived from spatial interaction of immune cell families are associated with survival in NSCLC patients post-immunotherapy
Presenter: sara arabyarmohammadi
Session: Poster session 20
1465P - Clinical impact of proton pump inhibitor on the therapeutic outcome of non-small cell lung cancer patients with PD-L1 TPS ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor plus chemotherapy: A retrospective multicenter cohort study
Presenter: Hayato Kawachi
Session: Poster session 20
1470P - Statin use and overall mortality in patients with advanced non-small cell lung cancer receiving anti-PD(L)1 immunotherapy: A SEER Medicare database analysis
Presenter: Joshua Reuss
Session: Poster session 21